Bone Care International Announces Fourth Quarter 2001 Revenues.Business Editors MIDDLETON, Wis.--(BUSINESS WIRE)--July 10, 2001 Bone Care International, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BCII BCII Battle Command and Intelligence Integration ) announced today that revenues for the fourth quarter ended June 30, 2001 were approximately $2 million, almost $1 million below the average of the analysts' expectations. Sales of Hectorol Injection continue to be hindered by the lack of a nationwide Medicare billing code; two competitive D-hormones, both of which have nationwide billing codes, dominate the $600 million market in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . Several Medicare insurers have taken steps in the last week to implement local reimbursement codes in response to requests for coverage. Bone Care estimates that reimbursement is now available to approximately 45 percent of the 250,000 hemodialysis patients in the United States. Bone Care expects a nationwide Medicare billing code for Hectorol Injection on January 1, 2002. Bone Care plans to release its full quarterly financial results on August 6, 2001. Management invites interested parties to attend a conference call (800-273-9672) at 10:00 AM central time, or via the internet at bonecare.com. Bone Care is a pharmaceutical company engaged in discovering, developing and commercializing improved vitamin D-hormone therapies to treat secondary hyperparathyroidism secondary hyperparathyroidism Endocrinology ↑ Parathyroid activity with overproduction of PTH due to parathyroid hyperplasia in response to an extraparathyroid defect that results in ↓ Ca2+ Etiology Rickets, vitamin D deficiency, chronic renal failure in patients with kidney, or renal disease Renal disease Kidney disease. Mentioned in: Glycogen Storage Diseases hypertension High blood pressure Cardiovascular disease An abnormal ↑ systemic arterial pressure, corresponding to a systolic BP of > 160 mm Hg , and osteoporosis, and other diseases including psoriasis and cancers of the prostate, breast and colon. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion